Activist hedge fund Parvus builds stake in Novo Nordisk, FT reports
Published on 10/06/2025 at 04:14

Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
482.50 DKK | -1.13% |
|
-6.62% | -22.70% |
19/06 | US judge upholds FDA's removal of Ozempic, Wegovy from drug shortage list | RE |
19/06 | US judge upholds FDA's removal of Ozempic, Wegovy from drug shortage list | RE |
Published on 10/06/2025 at 04:14
Mr. Lars Fruergaard Jørgensen is a Vice President at European Federation of Pharmaceutical Industries & Assns, a Vice Chairman-Supervisory Board at Carlsberg A/S, a Member-Supervisory Board at Carlsberg Breweries A/S, a President & Chief Executive Officer at Novo Nordisk Ltd., a President & Chief Executive Officer at Novo Nordisk A/S and a Chairman at Harno Invest A/S. He is on the Board of Directors at Carlsberg A/S and Carlsberg Breweries A/S. Mr. Jørgensen was previously employed as a Member-Supervisory Board by Innate Pharma SA, a Vice President-Finance & Information Technology by Novo Nordisk Pharmaceutical SAS, and a Chairman by NNE Pharmaplan A/S. He also served on the board at ZymoGenetics, Inc. and NNIT A/S. He received his graduate degree from the University of Aarhus.
View full profileSelect your edition
All financial news and data tailored to specific country editions